Independent Director — PE-Backed Occupational Health and Workforce Medical Services | Clinical Independence, Employer Contracts and Integration

Enterprise context

The company provides workplace-related medical assessments, surveillance, onsite clinical services, emergency support and employee health programmes under contracts with employers. It operates at the boundary between clinical duty, workforce safety, employment decisions and sensitive personal information. The paying customer is usually the employer, but the individual receiving care remains entitled to informed, competent and confidential clinical treatment.

The company is expanding organically and through acquisitions. Scale can create consistent protocols and better access, but it can also amplify errors, conflicted reporting and weak consent. Commercial pressure may encourage rapid assessments, broad declarations of fitness, unnecessary testing or disclosure of information beyond a legitimate purpose. The Board seeks an Independent Director who will defend clinical independence while building disciplined contract economics and integration.

Core Board mandate

The Director will oversee clinical quality, professional accountability, consent, fitness-for-work governance, health-data privacy, onsite emergency readiness, employer contracting, laboratory and referral relationships, acquisition diligence and sponsor-aligned value creation. The appointee must be able to challenge both management and the financial sponsor where growth targets could compromise clinical standards.

The Director will help define what the company may properly communicate to an employer and what must remain within the clinical relationship. The role also requires scrutiny of whether programmes produce meaningful health and safety outcomes or merely generate tests, visits and dashboards.

Strategic and governance agenda

1. Protect clinical independence. Establish that clinical judgments, referrals and restrictions are made by qualified professionals using appropriate evidence—not to satisfy production, attendance or contract-renewal pressure.

2. Govern consent and purpose. Ensure individuals understand the assessment, who receives which result, how information will be used and the consequences of declining. Broad employment consent should not authorise unrelated secondary use.

3. Define fitness-for-work decisions. Review role-demand assessment, temporary restrictions, specialist escalation, reassessment, documentation and appeal. Reports should disclose functional conclusions without unnecessary diagnostic detail.

4. Assure clinical protocols. Govern medical history, examination, tests, equipment, calibration, interpretation, record completion and deviation. Protocols should be risk-based and updated through accountable clinical leadership.

5. Strengthen onsite emergency readiness. Examine staffing, medicines, equipment, escalation, transport, communications, drills and integration with the customer's incident command. Contracted presence is not evidence of response capability.

6. Protect health data. Apply minimum access, clinical segregation, secure employer reporting, retention, deletion, breach response and restrictions on analytics. Sales and account teams should not access identifiable clinical detail.

7. Govern laboratories and referrals. Review competence, quality events, sample identity, turnaround, pricing, conflicts, abnormal-result escalation and continuity. Referral economics must not influence clinical necessity.

8. Make contract economics complete. Include clinician time, travel, equipment, consumables, emergency readiness, reporting, supervision, data security, repeat visits, customer-specific requirements and receivable days.

9. Manage employer expectations. Contracts should define clinical boundaries, customer responsibilities, information sharing, emergency scope, staffing assumptions, access, liability and change control. Commercial teams cannot promise clinical outcomes.

10. Measure outcomes responsibly. Track follow-up completion, condition detection, restriction review, emergency response, occupational exposure trends and closure of workplace recommendations. Test volume alone is not a health outcome.

11. Protect clinicians and frontline staff. Review workload, competence, supervision, occupational exposure, fatigue, harassment, escalation rights and professional indemnity. Incentives should not depend primarily on tests or clearances completed.

12. Create acquisition discipline. Assess clinical records, licences, practitioner credentials, consent, laboratory quality, data security, claims, customer contracts and owner dependence before valuation.

13. Govern integration. Require early credential verification, protocol alignment, access reset, incident review, customer communication and migration to common clinical and data standards. Synergies must not precede safety controls.

14. Maintain financial resilience. Stress-test customer loss, clinician shortage, material claim, data breach, delayed integration, regulatory restriction and reimbursement delay. Liquidity must support patient remediation and continuity.

Board decisions requiring independent judgment

The Director will contribute to acquisitions, entry into new clinical services, large employer contracts, onsite staffing models, laboratory partnerships, remote consultation, health analytics, insurance arrangements, debt levels and strategic exit options.

Every new service should identify clinical evidence, practitioner competence, consent, information recipients, escalation, liability, economics and discontinuation pathway. Every acquisition should receive independent clinical and privacy diligence separate from commercial diligence.

Clinical quality and ethics assurance

The Board dashboard should include credentialing gaps; protocol deviations; abnormal-result follow-up; fitness decision appeals; emergency response events; consent exceptions; inappropriate disclosures; data incidents; laboratory corrections; clinical complaints; employee workload; contract contribution; receivables; integration milestones; insurance matters; and unresolved audit findings.

Assurance should combine clinical-record review, consent testing, equipment checks, employer-report sampling, practitioner interviews, laboratory tracing and onsite simulation. The Clinical Quality and Ethics Committee must be able to receive concerns directly from clinicians and affected individuals without commercial filtering.

Candidate profile

Candidates should have at least 22 years of senior experience across healthcare delivery, occupational medicine, diagnostics, employer health, clinical governance, insurance, data protection, audit, finance or private equity portfolio oversight. At least one dimension of the candidate's career should demonstrate direct responsibility for clinical quality, regulated health operations or independent healthcare governance.

Suitable candidates may include former healthcare CEOs, medical directors, clinical-quality leaders, CFOs, risk officers, payer executives, operating partners or Audit Committee Chairs. The candidate must be able to protect professional standards while understanding enterprise customers, acquisition economics and distributed service delivery.

Eligibility, independence and conflicts

Active inclusion in the IICA Independent Directors Databank is mandatory. The appointee must remain independent of the sponsor, founders, management and major customers. Relationships with employers, healthcare providers, laboratories, insurers, pharmaceutical or device suppliers, technology vendors, lenders, investors or acquisition targets must be disclosed.

The role may not be used to generate clinical referrals, insurance placement, diagnostic volume, consulting work or transactions for a connected party. Enhanced confidentiality will apply to clinical and employer information.

First 100-day priorities

• Observe onsite and clinic-based services and trace representative clinical pathways.
• Review serious incidents, fitness disputes, consent exceptions, disclosures and abnormal-result follow-up.
• Examine practitioner credentialing, laboratory oversight and emergency-readiness evidence.
• Reconstruct economics for major contracts after full clinical and data obligations.
• Assess recent acquisitions against the common quality and privacy baseline.
• Establish independent escalation thresholds for clinical, ethical and data concerns.

First-year outcomes

Success should mean demonstrable clinical independence, clearer fitness-for-work governance, protected health data, outcome-led reporting, complete contract economics and acquisitions integrated to a single quality standard. The company should create value because it earns trust from both employers and individuals—not because one party's interests are allowed to dominate the other's.